As for early clinical evidence example, Galanis et al. reported a phase I trial that engineered oncolytic measles virus that expressed carcinoembryonic antigen (CEA) was well tolerated and resulted in improved median survival time for recurrent ovarian cancer patients (132). The gene discussed is CEACAM5; the disease is ovarian carcinoma.